Guidant Heart Failure ICD Trials Showing Significant Decrease In Hospital Stay
This article was originally published in The Gray Sheet
Implantable cardioverter defibrillators (ICDs) are cost-effective in the long run for treating patients with congestive heart failure (CHF), said Guidant VP and Treasurer Todd McKinney asserted at a Dec. 14 ING-Barings health care conference in New York City.
You may also be interested in...
FDA is seeking "cardiologists with a special interest in congestive heart failure," in addition to interventional cardiologists, electrophysiologists, invasive (vascular) radiologists and vascular and cardiothoracic surgeons to fill three voting positions on its Circulatory System Devices Panel that will open June 30, 2000, according to an Oct. 13 notice appearing in the Federal Register.
Using electrophysiology electrode catheters to induce ventricular tachycardia can better guide physicians in developing treatment options for patients with coronary artery disease and at-risk for sudden cardiac death (SCD) according to the results of a National Heart Lung and Blood Institute-sponsored study released May 13.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.